Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Net Assets
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited net assets. Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has net assets worth €41.89 Billion EUR (≈ $48.98 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€89.76 Billion ≈ $104.94 Billion USD) and total liabilities (€47.87 Billion ≈ $55.96 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore GU5 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €41.89 Billion |
| % of Total Assets | 46.67% |
| Annual Growth Rate | 15.62% |
| 5-Year Change | 27.95% |
| 10-Year Change | 127.05% |
| Growth Volatility | 26.12 |
Net Assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)
Net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025. This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets have evolved over time, based on quarterly financial data. See GU5 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)
The table below shows the annual net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025. For live market cap and overall valuation, see Guangzhou Baiyunshan Pharmaceutical Hold stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €40.08 Billion ≈ $46.86 Billion |
+6.12% |
| 2024-12-31 | €37.77 Billion ≈ $44.16 Billion |
+2.98% |
| 2023-12-31 | €36.68 Billion ≈ $42.88 Billion |
+9.04% |
| 2022-12-31 | €33.64 Billion ≈ $39.33 Billion |
+7.38% |
| 2021-12-31 | €31.33 Billion ≈ $36.62 Billion |
+11.07% |
| 2020-12-31 | €28.21 Billion ≈ $32.97 Billion |
+8.53% |
| 2019-12-31 | €25.99 Billion ≈ $30.38 Billion |
+12.30% |
| 2018-12-31 | €23.14 Billion ≈ $27.06 Billion |
+20.15% |
| 2017-12-31 | €19.26 Billion ≈ $22.52 Billion |
+9.12% |
| 2016-12-31 | €17.65 Billion ≈ $20.64 Billion |
+103.29% |
| 2015-12-31 | €8.68 Billion ≈ $10.15 Billion |
+9.62% |
| 2014-12-31 | €7.92 Billion ≈ $9.26 Billion |
+12.81% |
| 2013-12-31 | €7.02 Billion ≈ $8.21 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 665.5% over the analyzed period, indicating profitable operations and earnings retention.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Net Assets Breakdown (December 2025)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €23.38 Billion | 61.88% |
| Other Components | €14.41 Billion | 38.12% |
| Total Equity | €37.79 Billion | 100.00% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Market Cap
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Zqgame
SHE:300052
|
$372.84 Million |
|
Shandong Liancheng Precision Manufacturing Co Ltd Class A
SHE:002921
|
$372.98 Million |
|
American Exceptionalism Acquisition Corp. A
NYSE:AEXA
|
$373.10 Million |
|
Guangdong Banbao Toy Co Ltd
SHG:603398
|
$373.12 Million |
|
Chongqing Mas Sci&Tech
SHE:300275
|
$372.74 Million |
|
Bonree Data Technology Co Ltd
SHG:688229
|
$372.67 Million |
|
LB Foster Company
NASDAQ:FSTR
|
$372.61 Million |
|
Simulations Plus Inc
NASDAQ:SLP
|
$372.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,904,527,869 to 37,788,048,347, a change of 1,883,520,478 (5.2%).
- Net income of 2,983,113,595 contributed positively to equity growth.
- Dividend payments of 1,647,590,738 reduced retained earnings.
- Other factors increased equity by 547,997,622.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.98 Billion | +7.89% |
| Dividends Paid | €1.65 Billion | -4.36% |
| Other Changes | €548.00 Million | +1.45% |
| Total Change | €- | 5.25% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €11.61 | €1.45 | x |
| 2018-12-31 | €13.34 | €1.45 | x |
| 2019-12-31 | €14.88 | €1.45 | x |
| 2020-12-31 | €16.08 | €1.45 | x |
| 2021-12-31 | €17.88 | €1.45 | x |
| 2022-12-31 | €19.72 | €1.45 | x |
| 2023-12-31 | €21.48 | €1.45 | x |
| 2024-12-31 | €22.08 | €1.45 | x |
| 2025-12-31 | €23.24 | €1.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.89%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.84%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 2.24x
- Recent ROE (7.89%) is below the historical average (12.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.35% | 5.57% | 1.44x | 1.79x | €296.87 Million |
| 2014 | 15.50% | 6.35% | 1.32x | 1.85x | €423.63 Million |
| 2015 | 15.39% | 6.80% | 1.21x | 1.88x | €455.27 Million |
| 2016 | 8.69% | 7.53% | 0.77x | 1.49x | €-226.48 Million |
| 2017 | 10.92% | 9.84% | 0.74x | 1.50x | €174.50 Million |
| 2018 | 15.87% | 8.15% | 0.82x | 2.37x | €1.27 Billion |
| 2019 | 13.19% | 4.91% | 1.14x | 2.35x | €770.40 Million |
| 2020 | 11.15% | 4.73% | 1.03x | 2.29x | €300.76 Million |
| 2021 | 12.80% | 5.39% | 1.04x | 2.28x | €813.66 Million |
| 2022 | 12.37% | 5.60% | 0.95x | 2.33x | €760.01 Million |
| 2023 | 11.61% | 5.37% | 0.96x | 2.25x | €563.75 Million |
| 2024 | 7.90% | 3.78% | 0.92x | 2.28x | €-754.96 Million |
| 2025 | 7.89% | 3.84% | 0.92x | 2.24x | €-795.69 Million |
Industry Comparison
This section compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $-674,404,204
- Average return on equity (ROE) among peers: -9.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) | €41.89 Billion | 14.35% | 1.14x | $372.78 Million |
| AKSO HEALTH GR. (SPADR)/3 (8HX) | $199.15 Million | -67.78% | 0.08x | $1.60 Billion |
| EDAP TMS S.A (EDA) | $26.25 Million | -7.45% | 1.10x | $132.10 Million |
| CLOUDR GROUP LTD. (H3L) | $-7.16 Billion | 0.00% | 0.00x | $23.02 Million |
| Medios AG (ILM1) | $7.38 Million | 0.00% | -0.40x | $289.23 Million |
| M1 Kliniken AG (M12) | $30.26 Million | 16.55% | 0.06x | $300.08 Million |
| Paragon Care Limited (PXS) | $192.32 Million | -7.48% | 1.00x | $130.61 Million |
| Sigma Healthcare Limited (S5YA) | $538.59 Million | 9.87% | 1.08x | $19.74 Billion |
| TELES Informationstechnologien AG (TLIK) | $55.51 Million | 20.17% | 0.56x | $1.09 Million |
| COSMOS HEALTH NEW DL-01 (V67A) | $36.04 Million | -51.45% | 0.83x | $14.90 Million |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more